RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., the world leader in rational genome engineering, today announced that it has filed a lawsuit against Cellectis SA and its affiliates Cellectis bioresearch and Cellectis bioresearch Inc. in the U.S. District Court for the Eastern District of North Carolina. The lawsuit seeks a ruling that Cellectis’ manufacture, use and sale of certain engineered meganucleases infringe U.S. Patent No. 8,021,867, a recently-issued patent related to Precision’s Directed Nuclease EditorTM (DNE) meganuclease technology. The lawsuit requests monetary damages as well as a permanent injunction preventing Cellectis from making, using, selling, offering for sale, or importing infringing engineered meganucleases in the United States.
